Back to search

Article

IGLV3-21 <sup>R110</sup> -directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

2025-02-07

Abstract excerpt

<h4>ABSTRACT</h4> We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21 R110 ) for selective targeting of a poor-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
45783b23-f011-5d56-8e3d-85fae33ffef3
DOI
10.1101/2025.02.04.636461
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
IGLV3-21 <sup>R110</sup> -directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemiaDOI 10.1101/2025.02.04.636461
Mutation-specific CAR T cells as precision therapy for IGLV3-21 <sup>R110</sup> expressing high-risk chronic lymphocytic leukemiaSemantic proximity
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.Semantic proximity
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity
IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.Semantic proximity
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity
A CHIMERIC RECEPTOR ENABLING ANTIBODY-GUIDED RETARGETING OF CAR T- CELLSSemantic proximity
The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemiaSemantic proximity
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.Semantic proximity
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)Semantic proximity
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.Semantic proximity
AI-Guided CAR Designs and AKT3 Degradation Synergize to Enhance Bispecific and Trispecific CAR-T Cell Persistence and Overcome Antigen EscapeSemantic proximity
CAR T cell engineering impacts antigen-independent activation and co-inhibitionSemantic proximity
Select a neighboring publication to make it the new centre.